-
Innovation Ranking
NewInnovation Ranking – Aurobindo Pharma Ltd
Aurobindo Pharma Ltd (Aurobindo) is a vertically integrated pharmaceutical company that manufactures and markets generic pharmaceuticals and active pharmaceutical ingredients (APIs). Its product portfolio is spread across major therapeutic and product categories including antibiotics, anti-retroviral, systemic gastroenterological, central nervous system, cardiovascular, anti-allergies, anti-diabetics, other therapeutic areas. The company also produces novel proprietary biocatalysts, vitamins, minerals, dietary supplements, sports nutrition, functional foods, weight loss products and fermentation-based semi-synthetic products. Aurobindo operates manufacturing facilities in India, Brazil, Portugal and the US; and...
-
Company Insights
Innovation and Patenting activity of Aurobindo Pharma Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Aurobindo Pharma Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab Biosimilar in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
Post Menopausal Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Sivaganga Biomass Power Plant I
Sivaganga Biomass Power Plant I is a biopower project located in Tamil Nadu, India. The project is owned by Aurobindo Agro Energy Private Limited. The project came online in 2006. Empower your strategies with our Sivaganga Biomass Power Plant I report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Bevacizumab Biosimilar in Metastatic Colorectal Cancer Drug Details:Bevacizumab biosimilar is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-1015 in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AB-1015 in Peritoneal Cancer Drug Details:AB-1015 is under development for the treatment of ovarian cancer, fallopian...
-
Product Insights
Gonorrhea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gonorrhea Clinical Trials Market Overview The Gonorrhea clinical trial report consists of 338 trials. The report provides an overview of the Gonorrhea clinical trials scenario. The report provides top-line data relating to the clinical trials on Gonorrhea. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The...